The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
CRA bolsters Life Sciences Practice with appointment of Christopher Zealey as Vice President
“I am pleased to welcome Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “His areas of expertise include...